KAREN FREEMAN: Open Payments
NPI 1326420647 · ROSLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,756 in 65 payments from 14 companies in 2025. Trend: 2023 $1,868 · 2024 $1,384 · 2025 $1,756
Food & beverage: $1,567Education: $189
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 12 | $467 |
| Alnylam Pharmaceuticals Inc. | 19 | $413 |
| Abbott Laboratories | 6 | $177 |
| AstraZeneca Pharmaceuticals LP | 8 | $151 |
| PFIZER INC. | 6 | $144 |
| Vifor Pharma, Inc. | 1 | $122 |
| SCPHARMACEUTICALS INC. | 4 | $94 |
| ABIOMED | 2 | $49 |
| United Therapeutics Corporation | 2 | $37 |
| Novo Nordisk Inc | 1 | $25 |
Products named: AMVUTTRA, UPTRAVI, OPSUMIT, VYNDAQEL, CARDIOMEMS, Veltassa, FUROSCIX, FARXIGA.
Industry payments across NY — which companies pay providers there.
